Skip to main content

Advertisement

SpringerLink
Log in

Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the effects of topical pranoprofen 0.1 % on acute central serous chorioretinopathy (CSC).

Methods

The medical records of 52 cases (52 patients) of CSC were retrospectively reviewed. Twenty-six patients were treated with topical pranoprofen 0.1 % (treatment group) and 26 patients did not receive treatment (control group). Baseline and follow-up values for visual acuity, subfoveal choroidal thickness (SCT), subretinal fluid (SRF) maximum height, and central macular thickness (CMT) were examined and compared between groups.

Results

In the treatment group, mean SCT decreased from 365.5 ± 52.9 μm at baseline to 288.9 ± 36.1 μm at 6 months after initiation of treatment (p = 0.005). Both SRF maximum height and CMT were also decreased from baseline at 1 month (SRF maximum height, baseline: 221.5 ± 108.4, 1 month: 97.7 ± 54.3 μm, p = 0.002; CMT, baseline: 403.9 ± 114.6, 1 month: 270.1 ± 37.9 μm, p = 0.003). In the control group, SCT decreased throughout the follow-up period, but the change was not significant. Subretinal fluid maximum height and CMT were significantly decreased after 3 months in the control group (SRF, baseline: 265.4 ± 112.4 μm, 6 months: 64.8 ± 116.9 μm, p = 0.005; CMT, baseline: 459.1 ± 104.9 μm, 6 months: 304.6 ± 92.8 μm, p < 0.001). Visual acuity was improved from baseline in both groups after 6 months, but the improvement was only significant in the treatment group (p = 0.002). The rate of disease recurrence was lower in the treatment group (23 %) than in the control group (38 %), but this difference between groups was not statistically significant (p = 0.229, chi-square test).

Conclusions

Topical pranoprofen 0.1 % was effective in treating acute CSC, as demonstrated by an increase in visual acuity and a decrease in SRF, SCT, and CMT after treatment. These results suggest that topical pranoprofen 0.1 % may be useful in treating patients with acute CSC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Piccolino FC, Borgia L (1994) Central serous chorioretinopathy and indocyanine green angiography. Retina 14:231–242

    Article  CAS  PubMed  Google Scholar 

  2. Lacono P, Battaglia PM, Papayannis A, La Spina C, Varano M, Bandello F (2015) Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-014-2899-5

    Google Scholar 

  3. Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68:815–820

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Baran NV, Gürlü VP, Esgin H (2005) Long-term macular function in eyes with central serous chorioretinopathy. Clin Exp Ophthalmol 33:369–372

    Article  Google Scholar 

  5. Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, Rosenfeld PJ, Smiddy WE (2002) Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22:19–24

    Article  PubMed  Google Scholar 

  6. Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F (2011) Central serous chorioretinopathy: a pathogenetic model. Clin Ophthalmol 5:239–243. doi:10.2147/OPTH.S171820

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wang MS, Sander B, Larsen M (2002) Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 133:787–793

    Article  PubMed  Google Scholar 

  8. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S (2004) Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 111:244–249

    Article  PubMed  Google Scholar 

  9. Imamura Y, Fujiwara T, Margolis R, Spaide RF (2009) Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 29:1469–1473. doi:10.1097/IAE.0b013e3181be0a83

    Article  PubMed  Google Scholar 

  10. Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, Matsumoto A, Yoshimura N (2012) Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology 119:1666–1678. doi:10.1016/j.ophtha.2012.02.021

    Article  PubMed  Google Scholar 

  11. Ooto S, Tsujikawa A, Mori S, Tamura H, Yamashiro K, Otani A, Yoshimura N (2011) Retinal microstructural abnormalities in central serous chorioretinopathy and polypoidal choroidal vasculopathy. Retina 31:527–534. doi:10.1097/IAE.0b013e3181eef2db

    Article  PubMed  Google Scholar 

  12. Kim SW, Oh J, Kwon SS, Yoo J, Huh K (2011) Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. Retina 31:1904–1911. doi:10.1097/IAE.0b013e31821801c5

    Article  PubMed  Google Scholar 

  13. Spaide RF, Goldbaum M, Wong DW, Tang KC, Iida T (2003) Serous detachment of the retina. Retina 23:820–846

    Article  PubMed  Google Scholar 

  14. Park SY, Kim SM, Song YM, Sung J, Ham DI (2013) Retinal thickness and volume measured with enhanced depth imaging optical coherence tomography. Am J Ophthalmol 156(557–566), e2

    PubMed  Google Scholar 

  15. Yang L, Jonas JB, Wei W (2013) Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol 91:e358–362

    Article  PubMed  Google Scholar 

  16. Liegl R, Ulbig MW (2014) Central serous chorioretinopathy. Ophthalmologica 232:65–76. doi:10.1159/00036001419

    Article  PubMed  Google Scholar 

  17. Zhao L, Qu YX, Li MM, Wang YL (2012) Quantitative evaluation by optical coherence tomography of prophylactic efficiency of Pranopulin on macular edema after cataract surgery. Chin Med J (Engl) 125:4523–4525

    Google Scholar 

  18. Russo A, Costagliola C, Delcassi L, Parmeggiani F, Romano MR, Dell'Omo R, Semeraro F (2013) Topical nonsteroidal anti-inflammatory drugs for macular edema. Mediators Inflamm 2013:476525. doi:10.1155/2013/476525

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kim SJ, Flach AJ, Jampol LM (2010) Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 55:108–133. doi:10.1016/j.survophthal.2009.07.005

    Article  PubMed  Google Scholar 

  20. Chun BY, Kang SY, Song JS, Kim HM (2010) Comparison of the effects of prophylactic nonsteroidal anti-inflammatory drugs on macular edema after cataract surgery. J Korean Ophthalmol Soc 51:935–940

    Article  Google Scholar 

  21. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33:2096–2102. doi:10.1097/IAE.0b013e318297a07a

    Article  CAS  PubMed  Google Scholar 

  22. Singh RP, Sears JE, Bedi R, Schachat AP, Ehlers JP, Kaiser PK (2015) Oral eplerenone for the management of chronic central serous chorioretinopathy. Int J Ophthalmol 8:310–314. doi:10.3980/j.issn.2222-3959.2015.02.17

    PubMed  PubMed Central  Google Scholar 

  23. Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103–126. doi:10.1016/j.survophthal.2012.07.004

    Article  PubMed  PubMed Central  Google Scholar 

  24. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. doi:10.1016/j.preteyeres.2015.05.003

    PubMed  Google Scholar 

  25. Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT (2013) Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol 2:96–101

    PubMed  PubMed Central  Google Scholar 

  26. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765

    Article  PubMed  Google Scholar 

  27. Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, Freund B, Guyer DR, Slakter JS, Sorenson JA (1999) Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 128:63–68

    Article  CAS  PubMed  Google Scholar 

  28. Brandl C, Helbig H, Gamulescu MA (2014) Choroidal thickness measurements during central serous chorioretinopathy treatment. Int Ophthalmol 34:7–13. doi:10.1007/s10792-013-9774-y

    Article  PubMed  Google Scholar 

  29. Ratanasukon M, Bhurayanontachai P, Jirarattanasopa P (2012) High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study. BMC Ophthalmol 16:12–20. doi:10.1186/1471-2415-12-20

    Google Scholar 

  30. Akyol-Salman I, Leçe-Sertöz D, Baykal O (2007) Topical pranoprofen 0.1% is as effective anti-inflammatory and analgesic agent as diclofenac sodium 0.1% after strabismus surgery. J Ocul Pharmacol Ther 23:280–283

    Article  CAS  PubMed  Google Scholar 

  31. Hayasaka Y, Hayasaka S, Zhang XY, Nagaki Y (2003) Effects of topical corticosteroids and nonsteroidal anti-inflammatory drugs on prostaglandin e2-induced aqueous flare elevation in pigmented rabbits. Ophthalmic Res 35:341–344

    Article  CAS  PubMed  Google Scholar 

  32. Tsurumi K, Kyuki K, Yanagihara M, Hasegawa J, Fujimura H (1986) Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo[b, f]thiepin-2-yl)propionic acid. 5th communication: antiplatelet effect of the drug and antiinflammatory effect of its main metabolite. Arzneimittelforschung 36:1818–1822

    CAS  PubMed  Google Scholar 

  33. Yamada R, Yamada S, Ishii A, Tane S (1993) Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi 97:955–960

    CAS  PubMed  Google Scholar 

  34. Liu X, Wang S, Kao AA, Long Q (2012) The effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival HLA-DR expression in dry eyes. Cornea 31:1235–1239. doi:10.1097/ICO.0b013e31824988e5

    Article  PubMed  Google Scholar 

  35. Hosoi T, Sasaki M, Baba S, Ozawa K (2009) Effect of pranoprofen on endoplasmic reticulum stress in the primary cultured glial cells. Neurochem Int 54:1–6

    Article  CAS  PubMed  Google Scholar 

  36. Schalnus R (2003) Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 217:89–98

    Article  CAS  PubMed  Google Scholar 

  37. Liew G, Quin G, Gillies M, Fraser-Bell S (2013) Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 41:201–214. doi:10.1111/j.1442-9071.2012.02848.x

    Article  Google Scholar 

  38. Chin EK, Almeida DR, Roybal CN, Niles PI, Gehrs KM, Sohn EH, Boldt HC, Russell SR, Folk JC (2015) Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy. Clin Ophthalmol 11:1449–1156. doi:10.2147/OPTH.S86778

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Dong-A University Hospital, 3-1. Dongdaeshin-Dong, Seo-gu, Busan, 602-715, Republic of Korea

    Seoung Hyun An & Yoon Hyung Kwon

Authors
  1. Seoung Hyun An
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoon Hyung Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoon Hyung Kwon.

Ethics declarations

This study was approved by the Institutional Review Board of Dong-A University. Written informed consent was obtained from all participants, and all study conduct adhered to the tenets of the Declaration of Helsinki.

Conflicts of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Funding

This study was funded by the Dong-A University research fund. The sponsor had no role in the design or conduct of this research.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

An, S.H., Kwon, Y.H. Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254, 1489–1496 (2016). https://doi.org/10.1007/s00417-015-3215-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-015-3215-8

Keywords

Search

Navigation